Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;82(1):e11-e14.
doi: 10.1016/j.jinf.2020.08.032. Epub 2020 Aug 25.

SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on

Affiliations
Comment

SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on

Wolfgang Korte et al. J Infect. 2021 Jan.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig. 1
a-c: Overall (gender independent) course of anti-SARS-CoV-2 antibodies: a) anti-NC IgG; b) anti-SP IgG; c) anti-SP IgA. Local Polynomial Regression Fitting with 2 standard errors (dotted lines). Anti-NC IgG showed a significant increase (weeks 3 to 5) before a significant decline (weeks 8 to 10, all p < 0•0075, Wilcoxon test, 1a), as did anti-SP IgG (weeks 4 to 6 and weeks 8 to 10, all p< 0•012, 1b). Note the dichotomous IgA distribution, 1c.
Fig 2
Fig. 2
a-c: Sex specific course of anti-SARS-CoV-2 antibodies in females (green) and males (red): a) anti-NC IgG; b) anti-SP IgG; c) anti-SP IgA. Curves connect medians. Significant differences are seen weeks 6 - 7 (anti-NC IgG, all p<0•0054, Wilcoxon test, Fig. 2a); weeks 4 - 5 (anti-SP IgG, all p < 0•0004, Fig. 2b); and weeks 4 - 7 (anti-SP IgA, all p < 0•0095, Fig. 2c). Samples from predominantly male (77% of samples with OI > 20, p < 0•01, Fisher's exact test) patients with very high, dichotomically separated IgA antibody values were seen (inset 2c, see also 1c). Dotted lines separate increased (reactive) from non-increased antibody concentrations.

Comment on

References

    1. Tre-Hardy M., Blairon L., Wilmet A. The role of serology for COVID-19 control: population, kinetics and test performance do matter. J Infect. 2020;81(2):e91–ee2. - PMC - PubMed
    1. Qu J., Wu C., Li X. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 - PMC - PubMed
    1. Beavis K.G., Matushek S.M., Abeleda A.P.F. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. J Clin Virol. 2020;129 - PMC - PubMed
    1. Theel E.S., Harring J., Hilgart H., Granger D. Performance Characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol. 2020 - PMC - PubMed
    1. Kikkert M. Innate immune evasion by human respiratory RNA viruses. J Innate Immun. 2020;12(1):4–20. - PMC - PubMed